.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,946,245

« Back to Dashboard

Details for Patent: 8,946,245

Title:Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE), Fridman; Jordan S. (Newark, DE), Vaddi; Krishna (Kenneth Square, PA)
Assignee: Incyte Corporation (Wilmington, DE)
Filing Date:Mar 30, 2011
Application Number:13/076,176
Claims:1. A method of treating a disease selected from cachexia, polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), multiple myeloma, leukemia, lymphoma, breast cancer, acute myelogenous leukemia, acute lymphoblastic leukemia, and Castleman's disease in a patient, comprising administering to said patient a therapeutically effective amount of a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof, and a further therapeutic agent wherein said treating refers to ameliorating or inhibiting the disease in the patient.

2. The method according to claim 1, wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof.

3. The method according to claim 2, wherein said further therapeutic agent is a chemotherapeutic agent.

4. The method according to claim 3, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent simultaneously to the patient.

5. The method according to claim 3, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent sequentially to said patient.

6. The method according to claim 3, wherein about 5 to about 1000 mg of said compound or said salt is administered to said patient.

7. The method according to claim 2, wherein said disease is polycythemia vera (PV).

8. The method according to claim 2, wherein said disease is essential thrombocythemia (ET).

9. The method according to claim 2, wherein said disease is myeloid metaplasia with myelofibrosis (MMM).

10. The method according to claim 2, wherein said disease is chronic myelogenous leukemia (CML).

11. The method according to claim 2, wherein said disease is chronic myelomonocytic leukemia (CMML).

12. The method according to claim 2, wherein said disease is multiple myeloma.

13. The method according to claim 2, wherein said disease is leukemia.

14. The method according to claim 2, wherein said disease is lymphoma.

15. The method according to claim 2, wherein said disease is breast cancer.

16. The method according to claim 2, wherein said disease is acute myelogenous leukemia.

17. The method according to claim 3, wherein said chemotherapeutic agent is lenalidomide.

18. The method according to claim 17, wherein said method further comprises administering a corticosteroid to said patient.

19. The method according to claim 18, wherein said corticosteroid is prednisone.

20. The method according to claim 3, wherein said chemotherapeutic agent is a DNA-damaging agent.

21. The method according to claim 20, wherein said DNA-damaging agent is selected from melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, and carmustine.

22. The method according to claim 2, wherein said further therapeutic agent is selected from melphalan plus prednisone, doxorubicin, dexamethasone, and bortezomib.

23. The method according to claim 2, wherein said disease is cachexia.

24. The method according to claim 2, wherein said cachexia results from or is associated with cancer.

25. The method according to claim 2, wherein the disease is Castleman's disease.

26. The method according to claim 2, wherein the disease is acute lymphoblastic leukemia.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc